Focus research 2022 SigDyn team
Cross-regulation between PI3Ks
Can they be used to better prevent tumor progression?
PI3Ks are a family of three classes of enzymes essential to cell life and which are frequently deregulated in cancer. The dependence of tumors on different types of class I PI3Ks is governed by putative genetic mutations and the tumor context (inflammation, etc.). While knowledge of class II and III PI3Ks in cancer is still too limited, class I PI3Ks seem to be dependent on mechanisms similar to those responsible for tumoral growth. The future of anti-cancer therapies targeting PI3Ks lies in a better understanding of these enzymes and the simultaneous targeting of several classes of PI3Ks with innovative drugs.
This project, coordinated by Dr Benoit Thibault and Dr Julie Guillermet-Guibert, will benefit in 2022 from the permanent recruitment of Dr Benoit Thibault as an Inserm researcher.
To find out more about the IUCT-Oncopole and CRCT-Oncopole research focuses, please click here
![logo_crct_v-1 Centre de Recherches en Cancérologie de Toulouse](https://www.crct-inserm.fr/wp-content/uploads/2021/03/logo_crct_v-1.png)
Centre de Recherches contre le Cancer de Toulouse (Oncopole)
Toulouse - FR
Nous contacter
+33 5 82 74 15 75
Nous rejoindre ?
![InsermSeul_Rvb__noir](https://www.crct-inserm.fr/wp-content/uploads/2022/01/InsermSeul_Rvb__noir.png)
![Logo-CNRS](https://www.crct-inserm.fr/wp-content/uploads/2021/08/Logo-CNRS.png)
![logo-ut3](https://www.crct-inserm.fr/wp-content/uploads/2023/03/logo-ut3.jpg)